Abetimus
Abetimus is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way Abetimus is supposed to help treat Systemic Lupus Erythematosus and specifically nephritis.
References
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 (Clenoliximab, Keliximab, Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab, Rituximab, Ocrelizumab, Pascolizumab) • CD23 (Gomiliximab, Lumiliximab) • CD40 (Teneliximab, Toralizumab) • CD62L/L-selectin (Aselizumab) • CD80 (Galiximab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab)
BLyS (Belimumab) • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab)
T-lymphocyte ( Zolimomab aritox)
|
|
|
Unsorted
|
Atorolimumab, Cedelizumab, Fontolizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|